Difference of growth-inhibitory effect of Scutellaria baicalensis-producing flavonoid wogonin among human cancer cells and normal diploid cell

2007 ◽  
Vol 245 (1-2) ◽  
pp. 269-274 ◽  
Author(s):  
Mika Himeji ◽  
Takashi Ohtsuki ◽  
Harumi Fukazawa ◽  
Miho Tanaka ◽  
Shin-ichi Yazaki ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Human Cancer ◽  
Diploid Cell ◽  
Inhibitory Effect ◽  
Scutellaria Baicalensis ◽  
Growth Inhibitory Effect ◽  
Human Cancer Cells ◽  
Growth Inhibitory

scholarly journals BP-M345, a New Diarylpentanoid with Promising Antimitotic Activity

Molecules ◽  
2021 ◽  
Vol 26 (23) ◽  
pp. 7139
Author(s):  
Pedro Novais ◽  
Patrícia M. A. Silva ◽  
Joana Moreira ◽  
Andreia Palmeira ◽  
Isabel Amorim ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Spindle Assembly Checkpoint ◽  
Human Cancer ◽  
Antitumor Agent ◽  
Inhibitory Effect ◽  
Growth Inhibitory Effect ◽  
Human Cancer Cells ◽  
Antimitotic Activity ◽  
Growth Inhibitory

Previously, we reported the in vitro growth inhibitory effect of diarylpentanoid BP-M345 on human cancer cells. Nevertheless, at that time, the cellular mechanism through which BP-M345 exerts its growth inhibitory effect remained to be explored. In the present work, we report its mechanism of action on cancer cells. The compound exhibits a potent tumor growth inhibitory activity with high selectivity index. Mechanistically, it induces perturbation of the spindles through microtubule instability. As a consequence, treated cells exhibit irreversible defects in chromosome congression during mitosis, which induce a prolonged spindle assembly checkpoint-dependent mitotic arrest, followed by massive apoptosis, as revealed by live cell imaging. Collectively, the results indicate that the diarylpentanoid BP-M345 exerts its antiproliferative activity by inhibiting mitosis through microtubule perturbation and causing cancer cell death, thereby highlighting its potential as antitumor agent.

Novel Phytochemical Constituents and Anticancer Activities of the Genus, Typhonium

2020 ◽  
Vol 20 (12) ◽  
pp. 946-957 ◽  
Author(s):  
Shaik I. Khalivulla ◽  
Arifullah Mohammed ◽  
Kuttulebbai N.S. Sirajudeen ◽  
Mannur I. Shaik ◽  
Weibing Ye ◽  
...  
Keyword(s):  
Cancer Cells ◽  
Apoptotic Cell ◽  
Human Cancer ◽  
Inhibitory Effect ◽  
Anticancer Activities ◽  
Southeast Asians ◽  
Human Cancer Cells ◽  
Anticancer Properties ◽  
Chemical Structures ◽  
Growth Inhibitory

Background: Typhonium is the largest genus in the Araceae family (~70 species), distributed in South Asia, Southeast Asia and Australia. Typhonium is well-known for its ethnopharmacological uses, and Southeast Asians consider it as an alternative medicine to treat cancer. This review elucidated the confirmed chemical structures of the isolated compounds of Typhonium and emphasized on their anticancer activities against various human cancer cells. Methods: Among several species, Typhonium blumei, T. flagelliforme, T. divaricatum and T. giganteum were extensively studied due to the presence of a class of secondary metabolites. All the available reports on Typhonium were included and discussed in this article. Results: Until now several groups of compounds, namely amino acids (1, 2), cinnamic acid (3), fatty acids (4-14), glycerol derivatives (15-18) and cerebrosides (19-34), flavonoids (35), hydantoins (36-38), lignin monomers (39-44), nucleobases (45-48), pheophorbides (49-52), phthalate (53), terpene and steroids (54-59) and vitamins (60, 61) were isolated and characterized from Typhonium. These phytochemicals were investigated for their anticancer properties, and results confirmed the promising growth inhibitory effect and anticancer activities against human lung, breast, prostate and colon cancer cells. The anticancer activity of these compounds appears to be mediated through the induction of apoptotic cell death. These phytochemicals further reported to exhibit other pharmacological efficacies, including anti-inflammatory, antioxidant, antiviral, anti-allergic, neuroprotective and hepato-protective properties. Conclusion: This is the first review to summarize the anticancer properties of all isolated compounds of Typhonium genus with confirmed chemical structures. Further advanced studies are necessary to establish the detailed signaling pathways that are involved in the anticancer property of the compounds.

scholarly journals Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells

2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Bin Han ◽  
Naohiro Fujimoto ◽  
Mizuki Kobayashi ◽  
Tetsuro Matsumoto
Keyword(s):  
Prostate Cancer ◽  
Synergistic Effect ◽  
Cancer Treatment ◽  
Cancer Cells ◽  
Prostate Cancer Cell ◽  
Inhibitory Effect ◽  
Prostate Cancer Cells ◽  
Growth Inhibitory Effect ◽  
Prostate Cancer Treatment ◽  
Growth Inhibitory

Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears following those treatments. It is urgently required to identify better or alternative therapeutic strategies. The purpose of this study was to confirm the anti-cancer activity of zoledronic acid (Zol) and determine whether inhibition of geranylgeranylation in the mevalonate pathway could be a molecular target of prostate cancer treatment. We examined the growth inhibitory effect of Zol in prostate cancer cells (LNCaP, PC3, DU145) and investigated a role of geranylgeranylation in the anticancer activity of Zol. We, then, evaluated the growth inhibitory effect of geranylgeranyltransferase inhibitor (GGTI), and analyzed the synergy of GGTI and docetaxel by combination index and isobolographic analysis. Zol inhibited the growth of all prostate cancer cell lines tested in a dose-dependent manner through inhibition of geranylgeranylation. GGTI also inhibited the prostate cancer cell growth and the growth inhibitory effect was augmented by a combination with docetaxel. Synergism between GGTI and docetaxel was observed across a broad range of concentrations. In conclusion, our results demonstrated that GGTI can inhibit the growth of prostate cancer cells and has synergistic effect with docetaxel, suggesting its potential role in prostate cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document